Randomized Trialhigh evidence
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.
The lancet. Diabetes & endocrinology·October 30, 2026·PMID 42962687
Why it mattersOrforglipron is a small-molecule, non-peptide oral GLP-1 receptor agonist, offering a potential alternative to injectable GLP-1 therapies for obesity disease. This trial provides efficacy and safety data in a Japanese population, supporting its use in clinical practice where oral administration may improve adherence and patient preference.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled